Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:47:15 EDT Thu 23 Mar 2023
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:LLY from 2022-03-24 to 2023-03-23 - 80 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-03-14 16:30U:LLYNews ReleaseLilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting
2023-03-08 17:00U:LLYNews ReleaseLilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease
2023-03-08 09:00U:LLYNews ReleaseUS FDA accepts supplemental New Drug Application for Jardiance ‚ ® for children 10 years and older with type 2 diabetes
2023-03-06 10:30U:LLYNews ReleaseIntensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study
2023-03-03 14:58U:LLYNews ReleaseU.S. FDA Broadens Indication for Verzenio ‚ ® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
2023-03-01 08:00U:LLYNews ReleaseLilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month
2023-02-21 10:00U:LLYNews ReleaseLilly to Participate in Cowen's 43rd Annual Health Care Conference
2023-02-13 06:00U:LLYNews ReleaseLilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh
2023-02-07 10:00U:LLYNews ReleaseLilly to Participate in SVB Securities Global Biopharma Conference
2023-02-03 10:00U:LLYNews ReleaseLilly to Participate in Guggenheim Oncology Conference
2023-02-02 06:45U:LLYNews ReleaseLilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook
2023-01-27 14:07U:LLYNews ReleaseU.S. FDA Approves Jaypirca ¢ „ ¢ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor
2023-01-26 10:00U:LLYNews ReleaseLilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity
2023-01-24 06:30U:LLYNews ReleaseLilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park
2023-01-20 09:00U:LLYNews ReleaseUS FDA accepts supplemental New Drug Application for Jardiance ‚ ® for adults with chronic kidney disease
2023-01-19 18:00U:LLYNews ReleaseU.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
2023-01-19 10:00U:LLYNews ReleaseLilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement
2023-01-04 10:00U:LLYNews ReleaseLilly to Participate in the J.P. Morgan Healthcare Conference
2022-12-22 06:00U:LLYNews ReleaseLilly and ProQR to Expand RNA Editing Collaboration
2022-12-14 04:15U:LLYNews ReleaseLilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
2022-12-13 06:45U:LLYNews ReleaseLilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines
2022-12-12 17:30U:LLYNews ReleaseLoxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting
2022-12-12 15:26U:LLYNews ReleaseLilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend
2022-12-07 08:00U:LLYNews ReleasePhase III trial demonstrated Jardiance ‚ ® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
2022-12-06 15:00U:LLYNews ReleaseLilly Announces Updated Data from the Verzenio ‚ ® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology
2022-12-01 08:41U:LLYNews ReleaseLilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
2022-11-30 18:00U:LLYNews ReleaseLilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
2022-11-30 06:50U:LLYNews ReleaseLilly and Akouos Announce Expiration of Akouos Tender Offer
2022-11-29 10:00U:LLYNews ReleaseLilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement
2022-11-21 09:00U:LLYNews ReleaseLilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium
2022-11-16 10:00U:LLYNews ReleaseLilly to Participate in Evercore ISI HealthCONx Conference
2022-11-07 11:30U:LLYNews ReleaseLilly to begin rollout of Tempo(TM) Personalized Diabetes Management Platform
2022-11-04 10:30U:LLYNews ReleaseLandmark EMPA-KIDNEY trial showed significant benefit of Jardiance(TM) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
2022-11-03 09:00U:LLYNews ReleaseLoxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting
2022-11-01 06:25U:LLYNews ReleaseLilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress
2022-10-27 10:00U:LLYNews ReleaseLilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration
2022-10-19 10:00U:LLYNews ReleaseLilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement
2022-10-18 06:50U:LLYNews ReleaseLilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
2022-10-17 12:04U:LLYNews ReleaseLilly Declares Fourth-Quarter 2022 Dividend
2022-10-06 06:45U:LLYNews ReleaseLilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
2022-09-21 19:12U:LLYNews ReleaseFDA Approves Lilly's Retevmo(TM) (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
2022-09-08 08:15U:LLYNews ReleaseLebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials
2022-09-07 18:05U:LLYNews ReleaseLilly Announces Details of Presentations at ESMO Congress 2022
2022-08-31 10:00U:LLYNews ReleaseLilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-25 10:00U:LLYNews ReleaseLilly to Participate in Citi's 17th Annual BioPharma Conference
2022-08-11 08:30U:LLYNews ReleaseLilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly
2022-08-08 06:45U:LLYNews ReleaseLilly's Taltz(TM) (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience
2022-08-04 09:52U:LLYNews ReleaseLilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results
2022-08-04 06:25U:LLYNews ReleaseLilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements
2022-07-21 10:00U:LLYNews ReleaseLilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement
2022-06-29 06:45U:LLYNews ReleaseLilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
2022-06-27 13:26U:LLYNews ReleaseLilly Declares Third-Quarter 2022 Dividend
2022-06-13 21:50U:LLYNews ReleaseFDA Approves Lilly and Incyte's OLUMIANT(TM) (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
2022-06-07 00:01U:LLYNews ReleaseEight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
2022-06-06 19:00U:LLYNews ReleaseNew analyses of Mounjaro(TM) (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's(TM) 82nd Scientific Sessions(TM)
2022-06-05 16:30U:LLYNews ReleaseJardiance(TM) decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
2022-06-04 11:00U:LLYNews ReleaseLilly's AWARD-PEDS trial investigating use of Trulicity(TM) (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo
2022-06-04 10:02U:LLYNews ReleaseLilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
2022-06-03 10:00U:LLYNews ReleaseLilly to Participate in Goldman Sachs Global Healthcare Conference
2022-05-26 17:00U:LLYNews ReleaseLilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-25 13:15U:LLYNews ReleaseLilly plans to invest $2.1 billion in new manufacturing sites in Indiana
2022-05-24 03:01U:LLYNews ReleaseFifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
2022-05-23 17:00U:LLYNews ReleaseLilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA
2022-05-20 08:11U:LLYNews ReleaseCHMP Recommends Approval of Lilly and Incyte's OLUMIANT(TM) (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
2022-05-16 14:00U:LLYNews ReleaseLilly to Participate in UBS Global Healthcare Conference 2022
2022-05-13 17:54U:LLYNews ReleaseFDA approves Lilly's Mounjaro(TM) (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes
2022-05-11 06:45U:LLYNews ReleaseFDA Approves Lilly and Incyte's OLUMIANT(TM) (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
2022-05-06 14:00U:LLYNews ReleaseMary Lynne Hedley Elected to Lilly Board of Directors
2022-05-03 14:00U:LLYNews ReleaseLilly to Participate in Bank of America Securities 2022 Healthcare Conference
2022-05-02 14:26U:LLYNews ReleaseLilly Declares Second-Quarter 2022 Dividend
2022-04-28 06:25U:LLYNews ReleaseSolid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022
2022-04-28 06:15U:LLYNews ReleaseLilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
2022-04-20 09:00U:LLYNews ReleaseTackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
2022-04-19 10:00U:LLYNews ReleaseLilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement
2022-04-11 10:15U:LLYNews ReleaseLilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
2022-04-01 06:45U:LLYNews ReleaseLilly Presents Updated Data on Retevmo(TM) (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
2022-03-27 20:00U:LLYNews ReleaseInnovent and Lilly Expand Strategic Partnership in Oncology
2022-03-26 11:20U:LLYNews ReleaseNearly 40% of Adults with Alopecia Areata Taking OLUMIANT(TM) 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies
2022-03-26 09:20U:LLYNews ReleaseMajority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies
2022-03-24 06:45U:LLYNews ReleaseLilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer